SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies	Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-08-11		NCT04684108

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hangzhou Sumgen Biotech Co., Ltd.	8

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Beijing Chaoyang Hospital of Capital Medical University	Beijing	China	3
Beijing Jishuitan Hostipal	Beijing	China	1
Henan Cancer Hospital	Zhengzhou	China	57
Qilu Hospital of Shandong University	Jinan	China	7
Shanxi Norman Bethune Hospital	Taiyuan	China	1
Shengjing Hospital Affiliated to China Medical University	Shenyang	China	1
Shenzhen Second People's Hospital	Shenzhen	China	1
The First Affiliated Hospital of Bengbu Medical College	Bengbu	China	6
The First Affiliated Hospital of China Medical University	Shenyang	China	6
The Fourth Affiliated Hospital of Hebei Medical University	Shijiazhuang	China	1
The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	2
Wuhan University Central South Hospital	Wuhan	China	1
Wuxi Central Hospital	Wuxi	China	1
Xiangyang Central Hospital	Xiangyang	China	17